In this episode of IMPACT Medicom’s podcast series on Precision Medicine in Oncology we discuss:
· The initiatives developed by Colorectal Cancer Canada to help progress access to genomic profiling and precision medicine for all cancer patients
· The patient’s perspective on education, access, and value of genomic profiling
· Access to genomic profiling in Quebec
· The value of IMPACT Medicom’s comprehensive genomic profiling prioritization report: https://www.impactmedicom.com/publications/reports
Barry D. Stein is the President and CEO of Colorectal Cancer Canada and is himself a survivor of metastatic colorectal cancer. He is an established lawyer in the fields of commercial and corporate law with GWBR, LLP in Montreal, where he dedicates a significant portion of his practice to labour law, as well as litigation in health and administrative law. Barry is the past president of the Coalition Priorité Cancer au Québec. He is also past chair of the IQVIA Advisory Council for the Advancement of Health in Quebec and a member of the Board of Directors of the Canadian Personalized Healthcare Innovation Network, EXACTIS Innovation, and the Quebec Clinical Research Organization in Cancer (Q-CROC).
If you enjoy our podcast, please review and subscribe. For more podcasts, papers, and medical education programs, visit our website at: http://www.impactmedicom.com.